Eli Lilly and Company $LLY is Independence Bank of Kentucky’s 10th Largest Position

Independence Bank of Kentucky increased its position in Eli Lilly and Company (NYSE:LLY) by 3.3% in the first quarter, HoldingsChannel reports. The firm owned 14,293 shares of the company’s stock after acquiring an additional 460 shares during the period. Eli Lilly and Company accounts for about 1.7% of Independence Bank of Kentucky’s investment portfolio, making the stock its 10th biggest holding. Independence Bank of Kentucky’s holdings in Eli Lilly and Company were worth $13,146,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in LLY. Maryland Capital Advisors Inc. purchased a new position in shares of Eli Lilly and Company during the fourth quarter valued at $25,000. Osbon Capital Management LLC purchased a new stake in Eli Lilly and Company in the 4th quarter worth about $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in Eli Lilly and Company by 84.2% in the 3rd quarter. Vermillion & White Wealth Management Group LLC now owns 35 shares of the company’s stock worth $27,000 after acquiring an additional 16 shares in the last quarter. Basso Capital Management L.P. acquired a new stake in Eli Lilly and Company during the 4th quarter worth about $30,000. Finally, Maseco LLP boosted its position in Eli Lilly and Company by 466.7% during the 1st quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after acquiring an additional 28 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Bank of America raised its price target on Eli Lilly to $1,334 from $1,251 and kept a buy rating, signaling confidence that the company still has meaningful upside after its recent run. Benzinga article
• Positive Sentiment: Lilly announced that its Phase 2 neuropathic pain trial reached completion, adding another potentially valuable pipeline asset beyond its blockbuster GLP-1 franchise. TipRanks article
• Positive Sentiment: News flow highlighting record GLP-1 adoption and accelerating sales remains supportive, since Lilly’s obesity and diabetes drugs continue to be the main driver of earnings momentum. Motley Fool article
• Positive Sentiment: Additional analyst commentary has been upbeat, with other firms also lifting targets and framing Lilly as one of the strongest growth names in healthcare. TheStreet article
• Neutral Sentiment: Institutional buying and “best mutual funds” lists suggest Lilly remains a favored large-cap healthcare holding, but this is more a sentiment indicator than a direct catalyst. Yahoo Finance article
• Negative Sentiment: Tampa General’s lawsuit over allegedly pulled 340B discounts adds legal and reimbursement risk, which could create some investor caution around Lilly’s pricing and hospital-channel relationships. Healthcare Finance News article

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Leerink Partners upped their target price on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,135.00 and gave the company a “hold” rating in a research report on Monday, June 22nd. Wolfe Research reiterated an “outperform” rating and issued a $1,350.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Barclays increased their target price on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Finally, Bank of America boosted their price target on shares of Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the company a “buy” rating in a report on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,263.41.

Eli Lilly and Company Trading Down 2.3%

Shares of NYSE LLY opened at $1,189.06 on Friday. The business has a 50 day simple moving average of $1,098.66 and a 200 day simple moving average of $1,033.53. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $1,249.45. The stock has a market cap of $1.12 trillion, a price-to-earnings ratio of 42.24, a PEG ratio of 1.51 and a beta of 0.51. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The firm had revenue of $19.80 billion during the quarter, compared to analysts’ expectations of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The company’s revenue was up 55.5% compared to the same quarter last year. During the same period in the previous year, the company earned $3.34 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, research analysts predict that Eli Lilly and Company will post 35.81 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be issued a $1.73 dividend. The ex-dividend date is Friday, August 14th. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio is currently 24.58%.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.